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The macrolide antibiotic bafilomycin and the related synthetic compound SB 242784 are potent inhibitors of the vacuolar H+-ATPases (V-
ATPase). It is currently believed that the site of action of these inhibitors is located on the membrane bound c-subunits of V-ATPases. To address
the identification of the critical inhibitors binding domain, their specific binding to a synthetic peptide corresponding to the putative 4th
transmembrane segment of the c-subunit was investigated using fluorescence resonance energy transfer (FRET), and for this purpose a specific
formalism was derived. Another peptide of the corresponding domain of the c′ isoform, was checked for binding of bafilomycin, since it is not
clear if V-ATPase inhibition can also be achieved by interaction of the inhibitor with the c′-subunit. It was concluded that bafilomycin binds to the
selected peptides, whereas SB 242784 was unable to interact, and in addition for bafilomycin, its interaction with the peptides either corresponding
to the c- or the c′-subunit isoforms is identical. Since the observed interactions are however much weaker as compared to the very efficient binding
of both bafilomycin and SB 242784 to the whole protein, it can be concluded that assembly of all V-ATPase transmembrane segments is required
for an efficient interaction.
© 2006 Elsevier B.V. All rights reserved.Keywords: V-ATPase; Bafilomycin A1; Fluorescence; FRET1. Introduction
Vacuolar ATPases (V-ATPases) are responsible for proton
pumping in acidic organelles and plasma membranes of
eukaryotic cells and their activity is essential in a large variety
of cellular processes [1,2]. V-ATPases are composed of two
domains (Fig. 1A), a soluble domain (V1), where the catalytic
center for ATP hydrolysis is located, and a membrane bound
domain (V0), responsible for proton pumping. V0 contains
multiple subunits including the 16-kDa proteolipids (subunits c)
(4–5 copies) and their isoforms c′ and c″ (one copy each) [3],
expected to play a major role in proton translocation. The⁎ Corresponding author. Centro de Química-Física Molecular, Complexo I,
Instituto Superior Técnico, Lisbon, Portugal.
E-mail address: pclloura@alfa.ist.utl.pt (L.M.S. Loura).
0005-2736/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2006.07.006c-subunit contains 4 putative transmembrane domains, and an
essential glutamate residue located in the 4th putative
transmembrane sequence is expected to be the carrier of
protons across the membrane through protonation/deprotona-
tion events [4].
Through site-directed mutagenic studies it was reported that
mutations in three residues of the c-subunit of the V-ATPase
from Neurospora crassa conferred resistance to bafilomycin A1
(Fig. 1B) [5], a macrolide antibiotic inhibitor of V-ATPases
produced by Streptomyces griseus [6]. Two of these residues
reside in the same side of the putative 4th transmembrane helix
(F136 and Y143), and this helix side is exposed to the lipid
environment [7]. Immobilization of spin-labeled residues of c-
subunit by concanamycin A, a macrolide antibiotic very similar
in structure to bafilomycin A1, has also been observed [8]. Also
recently, six other sites where mutations induced resistance to
bafilomycin A1 were reported, and three of these are located in
Fig. 1. (A) V-ATPase structure (adapted from [2]). (B) V-ATPase inhibitors SB 242784 and bafilomycin A1.
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latter, two residues are located in the same helix side as F136
and Y143, pointing to the existence of an inhibitor binding site
on this protein surface. It is not clear yet if residues from other
helices (1 and 2) could also be part of this binding site and form
a binding pocket [9], as this structure would imply a different
helix organization than the one suggested from cysteine cross-
linking experiments [10].
The exact location and structure of the inhibitor binding site
remains a matter of discussion, and in the present study we aim
to detect the molecular requirements for bafilomycin A1 binding
through the use of a reductionist approach, using a simpler
model system, a synthetic c-subunit derived peptide expected to
mimic the putative 4th transmembrane segment of the V-
ATPase c-subunit (Fig. 2). Synthetic peptides have proven to be
useful tools in the characterization of ligand binding-sites on
proteins and in some cases these isolated peptides were capable
of ligand binding efficiencies identical to the intact protein [11–
16]. Additionally, peptide fragments corresponding to trans-
membrane sequences in intact membrane proteins were shown
to specifically disrupt the intact protein activity (likely by
competing with native transmembrane domains) [17], and
functional membrane proteins have already been reformed from
reconstituted isolated transmembrane segments [18–20], prov-
ing that isolated peptides corresponding to transmembrane
fragments are able to maintain specific information even when
incorporated in the absence of its neighboring transmembraneFig. 2. Primary sequence of the model peptides. The sequences correspond to the
putative 4th transmembrane segment of the V-ATPase c-(H4) and c′-(H4c′
subunit from Saccharomyces cerevisiae. Peptide H4A←E corresponds to a
modification of peptide H4 in which the glutamate residue was replaced by an
alanine. This mutation is underlined. The peptides were flanked by lysines to
increase the membrane anchoring.)segments. Similar to a previous study on synthetic peptides that
mimic the 7th putative helix of the Vph1p subunit of yeast V-
ATPase [21], flanking lysines were included in the design of the
model peptides used in the present study to stabilize the
transmembrane orientation due to the anchoring effect of the
lysine residue.
Another V-ATPase inhibitor, (2Z,4E)-5-(5,6-dichloro-2-
indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-
2,4-pentadienamide (SB 242784) (Fig. 1B), a synthetic
molecule developed by Farina and coworkers [22] which is
based on the presumptive pharmacophore of bafilomycin A1
[23], and whose mechanism of inhibition is therefore expected
to be similar, was proposed as an agent for a new therapeutical
strategy in osteoporosis disease due to its specificity for the
osteoclastic form of the enzyme [22,24]. Bafilomycines are
powerful toxins, since they do not present specificity for any
particular type of V-ATPases, inhibiting indiscriminately all
enzymes, and thus preventing their therapeutical use. The
reason for the difference in selectivity between the two
inhibitors is still unclear, especially when noting that the
inhibitor acts on the c-subunit that is extremely conserved
between c-subunits from enzymes of different origins. A
possible explanation would be the participation of the a-subunit
(part of the enzyme membrane bound domain—V0) (Fig. 1A) in
the inhibitory mechanism, since the isoform a3 is expressed
primarily in osteoclasts [25], and recent mutational studies
support this hypothesis [26]. However, in a recent study using
fluorescence resonance energy transfer (FRET), it was reported
that SB 242784 and concanamycin bound competitively to
isolated c-subunits, and SB 242784 was shown to bind to these
as strongly as to the entire V0 domain, apparently excluding a
contribution of the a-subunit to the inhibitor binding mechanism
[27]. The same authors also detected binding efficiencies of c-
subunit for SB 242784 consistent with the inhibitor′s IC50
values, whereas for concanamycin these were slightly lower
than expected [27]. Mutation of the tyrosine residue (Y143)
from the 4th putative transmembrane segment had different
effects on the conferred degree of resistance of yeast to
concanamycin and to SB 242784, even though both were
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reason, to be overlapping but not identical.
Subunits c and c′ present a very large degree of sequence
similarity, but mutations in subunit c′ homologous to those in
subunit c producing bafilomycin A1 insensitive strains have no
effect in bafilomycin resistance [9]. On the basis of these results,
Bowman and coworkers suggested that if c-subunit isoforms
possess bafilomycin-binding sites, then these should have lower
inhibitor affinities than in the c-subunit.
Using the UV absorption properties of bafilomycin A1
(acceptor), we applied FRET in an assay (Tyr is the donor) to
check for the existence of binding between the inhibitor and
synthetic peptides corresponding to the putative 4th trans-
membrane segment of the c and c′-subunits from the V-
ATPase of Saccharomyces cerevisiae in a lipidic environment.
The same methodology was applied in binding assays with
SB 242784. We detected binding of bafilomycin A1 to the
selected peptides, while for SB 242784 no interaction took
place.
2. Materials
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-
nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DOPE), 1,2-Dioleoyl-
sn-glycero-3-phosphocholine (DOPC), 1,2-Dioleoyl-sn-gly-
cero-3-[Phospho-rac-(1-glycerol)] (DOPG), 1,2-Dierucoyl-sn-
glycero-3-phosphocholine (DEuPC), 2-Lauroyl-sn-glycero-3-
phosphocholine (DLPC) and 1,2-Miristoyl-sn-glycero-3-phos-
phocholine (DMPC) were obtained from Avanti Polar Lipids
(Birmingham, AL). (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-meth-
oxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadiena-
mide (SB 242784) was synthesized as described elsewhere [22].
Bafilomycin A1 was obtained from LC Laboratories (Woburn,
MA). Peptides H4, H4A←E, and H4c′ (see Fig. 2) were
synthesized by Pepceuticals (Nottingham, UK). Trifluoroacetic
acid (TFA), 16-DOXYL-stearic acid (2-(14-Carboxytetrade-
cyl)-2-ethyl-4,4-dimethyl-3-oxazolidinyloxy) and 5-DOXYL-
stearic acid (2-(3-Carboxypropyl)-4,4-dimethyl-2-tridecyl-3-
oxazolidinyloxy) were obtained from Sigma-Aldrich (St.Louis, USA). Trifluoroethanol (TFE) was obtained from
Acrōs Organics (Geel, Belgium). Other fine chemicals were
obtained from Merck (Darmstadt, Germany).
3. Experimental procedures
3.1. Sample preparation
The peptides (Fig. 2) were solubilized in 100 μl of TFA and immediately
dried under a N2(g) flow. Following that, the peptide was suspended in TFE.
When the TFA solubilization step was not introduced, the solubility in TFE was
greatly reduced, and the peptide aggregation levels after reconstitution in lipid
bilayers were enhanced.
For peptide reconstitution in lipid bilayers, the desired amount of
phospholipids and solubilized peptide (and of the inhibitors in the inhibitor
binding studies) were mixed in chloroform and dried under a N2(g) flow. The
sample was then kept in vacuum overnight. Liposomes were prepared with
buffer Tris 10 mM pH 7.4. The hydration step was performed with gentle
addition of buffer at a temperature above the phospholipid main transition
temperature.
For the fluorescence quenching experiments with the N-DOXYL-stearic
acids, the nitroxide labeled fatty acids were 10% of the total lipid (molar
fraction).
3.2. CD measurements
CD spectroscopy was performed on a Jasco J-720 spectropolarimeter with a
450 W Xe lamp. Samples for CD spectroscopy were extruded 8 times on a
homemade extruder using polycarbonate filters of 0.1 μm. Peptide concentration
was always 40 μM.
3.3. Fluorescence spectroscopy
Steady-state fluorescence measurements were carried out with an SLM-
Aminco 8100 Series 2 spectrofluorimeter (with double excitation and emission
monochromators, MC400) in a right angle geometry. The light source was a
450 W Xe arc lamp and for reference a Rhodamine B quantum counter solution
was used. Correction of emission spectra was performed using the correction
software of the apparatus. 5 ×5 mm quartz cuvettes were used. All
measurements were performed at room temperature.
The emission spectrum from the tyrosine of peptide H4 was recorded
using an excitation wavelength of 270 nm. The tyrosine quantum yield of
peptide H4 in lipid bilayers was determined using quinine sulfate (ϕ=0.55)
as a reference [28].4. Results
4.1. Characterization of reconstituted peptides
When using a peptide as a model for a protein section, it is important that it retains the structural properties of the latter [21].
Therefore, it was important for the present study to accurately know the behavior of the peptides when incorporated in lipid
bilayers. The characterization focused on secondary structure, aggregation and position in the bilayer. The 4th transmembrane
segment from which the peptide is derived is expected to assume a α-helical structure inside the V-ATPase subunit c, and
therefore conditions that favor this type of structure should be determined and used throughout the study.
CD spectra of peptide H4 incorporated in DOPC at a lipid to protein ratio (L/P-molar ratio) of 50 revealed the presence of
different types of secondary structures (Fig. 3). Deconvolution of the spectrum with the CDNN CD Spectra Deconvolution v.
2.1 software recovered a fraction of about 40% of α-helical structure, 29% was reported to be random coil, while the
remaining was divided between the different types of β-sheet structure. When a L/P ratio of 25 was used, the fraction of α-
helical structure present decreased to 30.5%. The presence of increasing amounts of β-sheet structure at lower L/P ratios is an
indication of peptide aggregation [29]. It was not possible to obtain a reasonable quality CD spectrum with samples of larger
L/P ratios as those used in the inhibitor binding studies, as the lipid concentration became too high and large light scattering
problems arose.
Fig. 3. CD spectrum of peptide H4 incorporated in DOPC at an L/P of 50.
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Fluorescence from tyrosine residues is known to be quenched by several mechanisms besides FRET, namely interactions with other
residues side chains such as glutamate and aspartate, and uncharged forms of basic residues such as arginine, lysine and histidine, as
well as electron transfer to peptide α-carbonyl groups [30,31]. Considering this, it can be expected that peptides forming aggregates
will have a lower quantum yield than their monomeric counterparts. The quantum yield dependence of Tyr15 (corresponding to
Tyr142 in the native protein [32]) from reconstituted peptides on the lipid composition is shown in Fig. 4. The presence of anionic
phospholipids clearly increases the quantum yield of peptide H4. In liposome of pure zwitterionic phospholipids, the Tyr15 quantum
yield trend is: DEuPC< DOPC<DMPC<DLPC. This difference was not a peptide partition effect because the use of larger lipid
concentrations while keeping the same lipid to protein ratio did not result in increased Tyr15 quantum yields. This was expected from
the high hydrophobic character of the peptide. On the basis of the higher quantum yield, the anionic lipids seem to be a better choice
i.e., the protein fraction in the monomeric form is larger. However, it is necessary to check if the peptide in this type of membranes is
in the desired transmembrane configuration, or if it is adsorbed at the interface. This can be determined from differential quenching
data, as described below.
The Tyr15 transverse positions relative to the center of the bilayer, obtained by the parallax method [33] using fatty acids labeled
with a nitroxide at different depths, are also presented in Fig. 4. In the presence of anionic phospholipids, the peptides adopt a more
superficial position in the bilayer (8–11 Å from the center of the bilayer). It is probable that a population of peptide H4 remains in a
transmembrane orientation while another adopts a superficial location. A similar situation should be taking place when long chain
lipids are used (DEuPC), as the position recovered for Tyr15 (9 Å) is also more superficial than in the other pure zwitterionic
phospholipids (around 6 Å) and no significant difference is observed between saturated (DMPC) and unsaturated (DOPC)
phosphatidylcholines of similar acyl chain lengths. This Tyr15 position is in agreement with a scenario where peptide H4 is in a
transmembrane orientation, as this aromatic residue is only slightly displaced from the center of the peptide sequence. The
displacement to a more superficial location of the Tyr15 when different lipids were used (DOPG or DEuPC), is also in agreement
with a transmembrane orientation of the peptides in DOPC.Fig. 4. Position of the Tyr15 residue of peptide H4 as determined by the parallax method (dark bars) and relative fluorescence quantum yield of Tyr15 (light bars)
for the peptide incorporated in different lipid systems at an L/P of 100.
Fig. 5. (A): Model used for FRET simulations. The donor (Tyr15) is located 6 Å from the center of the bilayer while the acceptors can be located at different planes,
assuming a superficial location such as for NBD-DOPE (A1) or more buried positions such as for the V-ATPase inhibitors (A2). In case of aggregation the number of
protein–protein contacts increases while protein–lipid contacts decrease, as a result, Re (exclusion distance) increases. (B) H4 fluorescence quenching of Tyr15 of
peptide H4 due to FRET to NBD-DOPE in DOPC bilayers using a lipid to protein ratio of 50 (●) and 100 (○). Curve corresponds to an exclusion radius fit to the energy
transfer data using equations 1–5 (—). A value of 9 Å was recovered for Re. (–––) FRET simulation for a random distribution of acceptors around a donor with an
exclusion radius of 20 Å. n2 is the superficial concentration of labeled phospholipids (molecules per Å
2). The range of NBD labeled phospholipid to total phospholipid
ratios in this experiment was 0.4% to 2%. Inset: Overlap between tyrosine fluorescence emission ( ) and DOPE-NBD absorption spectrum (––), R0 (Tyr-NBD)=22 Å.
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100% DOPC at an L/P of 100, as this lipid is able to favor the transmembrane orientation for peptide H4. The problem of lateral
aggregation in the membrane nevertheless potentially remained, as in DOPC the tyrosine quantum yield was significantly lower
than in liposomes containing anionic phospholipids. The possibility of aggregation could however also be assessed, as described
below.
A FRET experiment was performed in order to determine the size of the possible aggregates. Using the Tyr15 as a donor and
NBD labeled DOPE as acceptors (NBD-DOPE), FRET efficiencies were obtained (Fig. 5B). Fitting the available theoretical models
for energy transfer between donor and acceptors in different planes [34] to our experimental data, we can recover an averaged
exclusion radius (Re) of the donor, defined as the minimum distance between the Tyr15 and the NBD labeled phospholipids (Fig.
5A). For a monomeric peptide this value should be around 10 Å as this is approximately the sum of the radius of a α-helix backbone
and that of a phospholipid molecule. Any significant increase from this value is likely to be reporting an extensive aggregation
phenomenon.
FRET efficiencies (E) are calculated from the degree of fluorescence emission quenching of the donor caused by the presence of
acceptors.
E ¼ 1 IDA
ID
¼ 1
Z l
0
iDA tð Þdt=
Z l
0
iD tð Þdt ð1Þ
iDAðtÞ ¼ iDðtÞ:qinterplanarðtÞ ð2Þ
where IDA and ID are the steady-state fluorescence intensities of the donor in the presence and absence of acceptors respectively.
iDA and iD are the donor decays in the presence and absence of acceptors. ρinterplanar is the FRET contribution arising from
energy transfer to randomly distributed acceptors in two different planes from the donors (two monolayer leaflets) [34].
qinterplanar ¼ exp 2n2pl21
Z l1ﬃﬃﬃﬃﬃﬃﬃ
l2
1
þR2e
p
0
1 expðtb31a6Þ
a3
da
( )
exp 2n2pl22
Z l2ﬃﬃﬃﬃﬃﬃﬃ
l2
2
þR2e
p
0
1 expðtb32a6Þ
a3
da
( )
ð3Þ
1782 F. Fernandes et al. / Biochimica et Biophysica Acta 1758 (2006) 1777–1786where bi = (R0
2/li)
2τD
−1/3, R0 is the Förster radius, n2 is the acceptor density in each leaflet, and l1 and l2 are the distance between
the plane of the donors and the two planes of acceptors. Using Eqs. (1)–(3), theoretical expectations for FRET efficiency in a
random distribution of acceptors can be calculated and converted to IDA/ID ratios. The Förster radius is given by:
R0 ¼ 0:2108ðJj2n4/DÞ1=6 ð4Þ
where J is the spectral overlap integral, κ2 is the orientation factor, n is the refractive index of the medium, and ϕD is the donor
quantum yield. J is calculated as:
J ¼
Z
f ðkÞeðkÞk4dk ð5Þ
where f(λ) is the normalized emission spectra of the donor and ε(λ) is the absorption spectra of the acceptor. The numeric factor
in Eq. (4) assumes nm units for the wavelength λ and Å units for R0.
Assuming the already determined value for Tyr15 position in the bilayer (6 Å from the center) and the distance from the center of
the bilayer of the NBD moiety in NBD labeled phospholipids (19 Å) [35], l1 and l2 were determined to be 13 and 25 Å, respectively.
Using Eqs. (4) and (5) the Förster radius of the Tyr-NBD donor–acceptor pair was determined to be R0=22 Å. In the fitting
procedure, these values are kept fixed and the only parameter being fitted is Re. The results from the experiment along with the curve
fitted from the theoretical model, are presented in Fig. 5B. Both sets of data (L/P=50 and 100) were fitted with a value of Re=9 Å,
matching the expectation for a monomeric peptide. In case there were aggregates at the protein concentrations used these must be
small enough so that the distances between Tyr15 and the surrounding phospholipids are not affected. From Eqs. (1)–(3) and using
the same parameter values described above as well as Re=20 Å (large aggregates), a FRET simulation was performed for the same
system and the obtained donor quenching curve is compared to our experimental values in Fig. 5B.4.2. Peptide inhibitor binding studies
Both bafilomycin A1 and SB 242784 absorb in the UV region and can act as acceptors for tyrosine in energy transfer experiments
(spectra are shown in Fig. 6 and 7). The Förster radius for the Tyr-bafilomycin A1 donor–acceptor pair is 20 Å, whereas for the Tyr-
SB 242784 pair it is 24 Å (Eq. (4)). A 3 mM concentration of lipid was used to ensure an almost complete incorporation of inhibitors
in the bilayer. SB 242784 partition coefficient to DOPC bilayers is 1.20×104 [36], and at the lipid concentration used 97% of the
inhibitor molecules are incorporated in the bilayer. The fraction of inhibitors not incorporated in the vesicles was taken into account
on the acceptor concentrations plot in Fig. 7, which depicts the Tyr15 quenching via energy transfer to SB 242784.
In contrast to SB 242784, bafilomycin A1 is not a fluorescent molecule and partition coefficients could not be determined using
photophysical techniques. Overestimation of its partition coefficient could lead to an underestimation of bafilomycin-peptide binding
constants. However, it was recently showed by EPR of spin-labeled lipids that the macrolide molecule concanamycin A, another
powerful V-ATPase inhibitor with very similar structure to bafilomycin A1, readily incorporates in lipid membranes [37]. Thus, it is
to be expected from this result and from the high hydrophobic character of the molecule that the incorporation of bafilomycin A1 at
the lipid concentrations used is close to 100%.
On the inhibitor-peptide binding assays, the L/P was kept at 100 in order to ensure minimum levels of aggregation. Experimental
FRET efficiencies obtained with both peptide H4/SB 242784 and peptide H4/bafilomycin A1 donor/acceptor pairs (Eq. (1)), are
compared to theoretical expectations for a random distribution of acceptors (the scenario in which there is an absence of binding)
obtained from Eqs. (1) and (2) (see Figs. 6 and 7). The position of SB 242784 in DOPC bilayers was already determined from
selective quenching methodology (parallax method) to be 12.8 Å from the center of the bilayer [36], but the position of the
bafilomycin A1 chromophore was impossible to determine by the same methodology since this molecule is not fluorescent. In Fig.
6A, the simulations corresponding to different positions of the bafilomycin A1 chromophore inside the bilayer are shown, together
with the experimental data. It is clear that even when assuming that the Tyr15 is located on the same bilayer plane as the bafilomycin
A1 chromophore (6 Å from the center of the bilayer), in a situation of maximal energy transfer efficiency, the experimental energy
transfer efficiencies cannot be solely explained by the unbound population of inhibitor molecules (i.e. random distribution of
acceptors) and a fraction of peptide H4 must be binding bafilomycin A1. It is difficult to precisely quantify the binding constant (Kb)
for this process due to the uncertainty relative to the bafilomycin A1 chromophore position in the bilayer, but a lower and a higher
limit can be determined assuming the closest and furthest position possible for bafilomycin A1 and Tyr15 (corresponding
respectively to a position in the center and in the surface of the bilayer for bafilomycin A1), and also that peptide H4/bafilomycin A1
complexes are completely non-fluorescent (Eqs. (6) and (7)). This last assumption is valid, since for a contact interaction either by
Förster type or other transfer (exchange) mechanism, the efficiency of transfer would be 100%. The equations valid for the FRET
efficiency in a scenario of peptide H4-bafilomycin A1 1:1 complex formation are given below:
EEXP ¼ Erandom þ H4 Baf½H4T
1 Erandomð Þ ð6Þ
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1 Kbð½Baf T þ ½H4T Þ þ
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ð1þ Kbð½Baf T þ ½H4T ÞÞ2  4ðK2b ½Baf T ½H4T Þ
q
ð2KbÞ½H4T
ð7Þ
where [H4-Baf] is the effective concentration (molecules per lipid volume as the binding is confined to the lipid phase) of the
peptide–bafilomycin A1 complex, and, [H4]T and [Baf]T are respectively, the effective analytical concentrations of the peptide and of
bafilomycin A1. EEXP is the energy transfer efficiencies obtained experimentally and Erandom is the theoretical energy transfer
efficiency assuming a random distribution of acceptors (Eqs. (1)–(3)). In case binding is detected, the use of effective bafilomycin A1
concentrations will result in lower binding constants as compared to the ones of bulk concentrations, but the binding constants
obtained in this way have a larger physical meaning as they will not change with lipid concentration. Anyway they can be easily
interconverted.
Assuming a position for bafilomycin A1 in the center of the bilayer, the fitting procedure (Fig. 6A) recovered Kb=10.5±1.32 M
−1
(mol per volume of lipid). When the bafilomycin A1 position was fixed to 20 Å from the center of the bilayer (i.e. at the surface), the
value recovered was Kb=36.2±2.8 M
−1. Therefore, the binding constant upper and lower bounds for the peptide H4–bafilomycin
A1 complex are 10.5±1.32<Kb<36.2±2.8 M
−1. However, it is to be expected that, due to the hydrophobic character of the
bafilomycin A1 molecule, the real value should be located near the lower limit of this interval.
The same experiment was performed using peptides H4A←E and H4c′ (Fig. 2)). In peptide H4A←E the glutamate, which
corresponds to the natural amino acid expected to play a key role in the proton translocation process, was changed to an alanine, and
peptide H4c′ corresponds to the 4th transmembrane helix of the c′ isoform of the c-subunit. Both peptides were characterized in
DOPC with identical results to peptide H4. The results for the inhibitor binding assays are shown in Fig. 6B. The recovered lower
bounds for the binding constants were: Kb(H4A←E)>20.6±4.46 M
−1 and Kb(H4c′)>13.72±3.05 M
−1.Fig. 6. (A) Fluorescence emission quenching of Tyr15 of peptide H4 by FRET to bafilomycin A1(●). Theoretical expectations (Eqs. (1–3)) for FRET in the absence of
inhibitorbinding topeptideH4assumingpositions forbafilomycinA1of12.5Å(⋯), 8.5Å(–––), and4.5Å(—) fromthecenterof thebilayer. ( )Fittingofequations6and
7 to FRETdata assuming a bafilomycinA1 position of 4.5Å from the center of the bilayer. The interval 10.5±1.34<Kb(H4-bafilomycin A1)<36.2±2.78was recovered. Inset:
Overlapbetween tyrosine fluorescenceemission ( ) andbafilomycinA1 absorption spectrum(–––),R0 (Tyr-bafilomycin A1)=20Å. (B)Fluorescence emissionquenchingof
peptide H4A←E (●) and peptide H4c′ (○) tyrosine by FRET to bafilomycin A1. Theoretical expectations (Eqs. (1–3)) for FRET in the absence of inhibitor binding to
peptideH4, assumingpositions for bafilomycinA1of 4.5Å from the center of thebilayer ( ). FRETdata fitted toEqs. 6 and7 assumingabafilomycinA1positionof 4.5Å
from the center of the bilayer. Kb(H4A←E-bafilomycin A1)≥20.6±4.46 (⋯) and Kb(H4c′-bafilomycin A1)≥13.7±3.05 (–––) were recovered. The range of bafilomycin to total
phospholipid ratios in these experiments was 0.25% to 2%.
Fig. 7. Fluorescence emission quenching of Tyr15 of peptide H4 by FRET to SB 242784 (●). Curve corresponds to the theoretical expectation for FRET in the absence
of inhibitor binding to peptide H4 (see text). The range of SB 242784 to total phospholipid ratios in these experiments was 0.18% to 1.8%. Inset: overlap between
tyrosine fluorescence emission ( ) and SB242784 absorption spectrum (–––), R0 (Tyr-SB 242784)=24 Å.
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7). With this inhibitor, the obtained FRET efficiencies matched the theoretical expectations for a random distribution of acceptors,
suggesting absence of binding between SB 242784 and the peptide. No uncertainty exists regarding this result as the position of
the inhibitor inside the bilayer is accurately know from parallax fluorescence quenching techniques (12.8 Å from the center of the
bilayer — [36]).5. Discussion
5.1. Use of peptide H4 as a model peptide for the 4th
transmembrane segment of subunit c
Aggregation of transmembrane peptides containing a hydro-
phobic sequence and flanked by basic residues has already been
reported [38–40], thus detection of aggregates of peptide H4 at
low L/P ratios (<50) was not surprising. The c-subunit of V-
ATPase is expected to be composed of 4 putative transmem-
brane segments tightly packed between themselves as well as
with other transmembrane segments from neighboring subunits
inside a hexamer. This preference for protein–protein interac-
tions as opposed to protein–lipid interactions is possibly what
drives the detected association between the H4 peptides
incorporated in liposomes as detected by CD spectroscopy at
low L/P ratios. However, at the higher L/P ratios allowed by
fluorescence spectroscopy, the presence of large aggregates can
be excluded as the average exclusion radius of the peptide
recovered from the data in Fig. 5B, is identical to the expectation
for monomeric species. It is clear from Fig. 5B that a scenario
where Re is significantly larger than 10 Å (as expected for large
aggregates) is not compatible with our results further validating
our conclusions.
It could be invoked that due to null or very low Tyr15
quantum yields of aggregated H4 peptides, the fraction of donor
light from aggregated species is negligible and the fraction of
fluorescence from monomeric peptides is largely dominant. In
such a case, the obtained FRET efficiencies only concern
monomeric peptides as donors and the fluorescence data from
FRET binding measurements to V-ATPase inhibitors would notbe affected by a population of aggregated peptides with low
exposure to bulk phospholipids in which the inhibitors binding
sites could be occluded. In both cases, we can expect that the
peptides containing unquenched tyrosines are exposed to the
lipid environment, ensuring accessibility towards inhibitors and
feasibility of the inhibitor binding assays (the lipid exposure of a
surface of the 4th transmembrane segment is in fact expected in
the intact c subunit [7,10]). From all of the above evidence, we
expect that peptide aggregation under our experimental condi-
tions is not biasing the data.
5.2. Inhibitor/Peptide FRET binding assays
The mechanism of inhibition of V-ATPase by macrolide
inhibitors as well as by synthetic molecules has recently been the
target of extensive study and debate [8,9,26,27]. It is still not
clear which domains of the enzyme contribute to the formation
of the inhibitors binding site. Bowman and coworkers identified
several mutations in the V-ATPase able to completely disrupt
bafilomycin A1 inhibitory activity, all of these located in the
c-subunit and the majority of them in the domain expected to
comprise the 4th transmembrane segment [5,9]. From FRET
measurements, it was shown that concanamycin and SB 242784
bound competitively to the c-subunit, clearly suggesting an
overlap of the inhibitor binding sites [27]. The dissociation
constants of the protein–inhibitor complex were also relatively
close to the published IC50 values for SB 242784. Therefore, it
seems that all structural requirements for inhibitor binding to the
membrane bound domain of the V-ATPase are located in the
c-subunits, even if particular domains in the a-subunit can play a
role in the inhibitory mechanism as proposed by some authors
1785F. Fernandes et al. / Biochimica et Biophysica Acta 1758 (2006) 1777–1786[26]. In the same way, c-subunit residues shown to be important
for bafilomycin A1 inhibitory activity through mutational
studies [9] could not be directly involved in the binding of the
inhibitor, but still play a role in the inhibition mechanism. Here,
we proposed to further define the structural requirements for
bafilomycin A1 and SB 242784 binding to the V-ATPase, by
focusing on the protein domain expected to be the primary
contributor to the inhibitor binding site, the putative 4th
transmembrane domain of the c-subunit. The extent of binding
efficiencies achieved using only peptides corresponding to this
section of the protein is an indicator of the relevance of the
remaining protein domains to the binding of inhibitor, the first
step in the inhibitory mechanism.
No evidence was found supporting SB 242784 association
with the peptide H4. On the other hand, bafilomycin A1 was
shown to possess only moderate affinity for the transmembrane
peptides. Due to uncertainties in bafilomycin A1 position in
bilayers it was impossible to rigorously quantify a binding
constant for the process, but a reliable range for this parameter
could be presented. The differences in bafilomycin A1 binding
efficiencies for the peptide H4, H4c′ and H4A←E are not
significant as they fall within, or close to the error of the fits. For
H4c′ this result is somewhat surprising. Mutations on conserved
residues of the c-subunit known to confer resistance to
bafilomycin A1 and concanamycin were shown to be ineffective
in the c′ and c′ isoforms [9]. It was proposed that if a
bafilomycin A1 binding site was present on these isoforms, then
it must possess lower affinity than in the c isoform [9]. If this is
the case, then the differences in binding efficiencies between the
two isoforms must be explained by discrepancies in the
interaction of the inhibitor with parts of the protein other than
the highly conserved putative 4th transmembrane helix.
Although the contribution from the 4th transmembrane
segment (TM4) to the binding site affinity for bafilomycin A1 is
not negligible, it is absolutely unable to explain the extremely
low IC50 of bafilomycin A1 (0.1 nM). The binding efficiencies
observed for concanamycin (IC50 close to bafilomycin A1) and
the intact isolated c-subunit [27] were more than 1000 times
larger than the ones recovered in the present study. Therefore, it
is clear that either: (i) the other transmembrane segments from
the c-subunit, namely TM1 and TM2, are essential in the
formation of an efficient inhibitor binding site, or that (ii)
interactions of TM4 with other protein segments are required for
this protein section to assume the appropriate folding which
enables the establishment of the necessary interactions for an
efficient binding between the residues of the 4th transmembrane
segment of the c-subunit and the inhibitors. Absence of SB
242784 binding to the peptide H4 could be explained by the
much lower IC50 of this inhibitor (26 nM in chicken osteoclasts
[22]) that reflects a much lower binding site affinity for this
inhibitor, and the absence of remaining c-subunit transmem-
brane segments potentiates this effect.
In this work, in addition to the detailed comparison of the
different inhibitors and peptides, it was concluded that in
contrast to some reported cases [11–16], there is a very
significant difference in binding when comparing the binding to
selected protein segments or to the whole protein. Althoughstudies using peptides are very relevant, clearly in the case of
the interaction between the bafilomycin A1 or SB 242784 with
the c-subunit from V-ATPase, the whole protein architecture
and the environment that it provides, are key factors for an
efficient binding.
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